GSK Files Blockbuster Hopeful Shingrix With FDA
The shingles vaccine is considered one of the products with the biggest commercial potential for GSK in the near-term.
You may also be interested in...
There's optimism around Novartis as it heads into its final quarter with Joe Jimenez in charge, while Lilly faces impending headwinds, GSK will be touting Shingrix for future growth as vaccines growth tempers, and Amgen treads a complicated path through the biosimilar landscape.
With new US President Trump in place, new corporate CEO Walmsley to take the reins in April and the opportunity for four US drug launches in 2017, GSK’s president of US Pharmaceuticals says he is preparing for an “intense” year.
The latest drug development news and highlights from our FDA Performance Tracker.